Punjab: Medical Officer, Nurse booked under IPC 304A for death of woman post delivery

Tarn Taran: In response to allegations of medical negligence leading to the death of a 31-year-old woman due to complications following childbirth, a medical officer and a nurse have been booked by the police in connection with the case. 

The woman delivered her child at Dhawan Nursing Home, Bhikhiwind but, she passed away at a private hospital in Amritsar after being transferred there due to her worsening condition following the delivery. 

The deceased has been identified as Sandeep Kaur, the wife of Harpreet Singh, a resident of Narili village.  

Also read- Anaesthesiologist, 2 Nurses Suspended After 3 Women Die Of Post-Surgical Infections At Karnataka Hospital

On March 29, the woman, a resident of Narili village was admitted to the Dhawan Nursing Home, Bhikhiwind for delivery. She gave birth to a baby girl however her condition became critical the next day as reported by The Tribune. 

Noting her condition she was shifted to an Amritsar-based private hospital from the Bhikhiwind on March 30 by the nursing home doctor. Later, she died on the same day at the private hospital. 

Following her death, the family members filed a complaint at a police station and the doctor-nurse duo were booked under Section 304A (Causing death by negligence) of the Indian Penal Code (IPC) on Sunday. Meanwhile, the incident has been informed to the higher authorities for further action. Both the accused are absconding, said the police.

Medical Dialogues team had earlier reported that a Government hospital doctor at Jambusar in Bharuch district was booked for alleged medical negligence while performing a caesarean delivery last September. The doctor has been accused of leaving a cotton swab inside the patient during the procedure. Meanwhile, the doctor has accused the patient’s family of “defaming” her and sent a legal notice to the patient’s husband, seeking Rs 50 lakh. 

Also read- Woman Dies After Gallbladder Surgery, Doctor Booked Under IPC 304A

Powered by WPeMatico

Atleast 50% more geographically distributed Govt sites be included: CDSCO panel Tells IQVIA in Milvexian study

New Delhi: Reviewing the proposal presented by IQVIA regarding the waiving of the specific condition in the Milvexian study, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined IQVIA that the condition may be modified as “At least 50% more geographically distributed and Government sites should be included in the study”.

This came after IQVIA presented a waiver to condition No.1 i.e. 50% of sites should be Govt. sites and 50% of trial subjects should be enrolled in these Govt. sites protocol No. 70033093AFL3002. It is a study of Milvexian versus Apixaban in participants with Atrial Fibrillation.

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.

Milvexian is a factor XIa inhibitor which acts as an anticoagulant. It is taken by mouth. As of late 2021, it was understudy for the prevention of blood clots in patients undergoing surgery.

Milvexian is a potent small molecule that inhibits the active form of FXIa with high affinity. This molecule is one of the first oral FXIa inhibitors being developed as a new potential antithrombotic drug.

At the recent SEC meeting for Cardiovascular and Renal held on 7th March 2024, the expert panel reviewed the proposal presented by IQVIA.

After detailed deliberation, the committee recommended that condition No. 1 may be modified as “At least 50% more geographically distributed Government sites should be included in the study.

Also Read: Drug safety alert: CDSCO flags 58 drug samples

Powered by WPeMatico

Abortion performed on wrong woman at Prague Hospital due to language barrier

In a shocking turn of events at a Prague hospital, a routine checkup for a pregnant woman turned into a nightmare as she became the unintended victim of a grave medical error. The incident, which occurred at Bulovka University Hospital, saw the woman undergoing an abortion procedure she never consented to, plunging her into unimaginable distress. On March 25, the woman, four months pregnant, found herself mistakenly placed under anesthesia and subjected to a uterine surgery intended for another patient. The hospital attributed this catastrophic blunder to a language barrier, exacerbating an already dire situation. The harrowing ordeal highlights not only the alarming lapse in patient identification but also underscores the critical need for effective communication protocols in healthcare settings. As investigations unfold and the affected woman grapples with the repercussions, questions loom over the adequacy of internal regulations and the accountability of the hospital staff involved.

Powered by WPeMatico

Lupin names Dr Ranjana Pathak as Chief Quality Officer

Mumbai: Global pharma major Lupin Limited today announced the appointment of Dr Ranjana Pathak as Chief Quality Officer, succeeding Johnny Mikell who will be retiring from the services of the company. With over three decades of industry experience, Dr Pathak brings a wealth of expertise and leadership and will oversee all aspects of quality and regulatory compliance for Lupin’s global operations.

Dr Pathak’s career includes serving as the Global Head for Quality and Pharmacovigilance at Dr. Reddy’s. Prior to this, Dr Pathak served as the President & Global Head of Quality, Medical Affairs and Pharmacovigilance at Cipla and has also held Global Quality and Compliance leadership positions at Watson/Actavis and Endo Pharmaceuticals in the U.S. Dr. Pathak has strong experience across generic and brand medicines across dosage platforms including injectables, inhalation products and biologics.

“We extend our gratitude to Johnny for his valuable contribution to Lupin over the past five years,” said Vinita Gupta, CEO and Nilesh Gupta, MD, Lupin. “We are delighted to welcome Ranjana to our executive leadership team. Her extensive global experience and proven track record in building and sustaining a strong culture of quality and compliance align with Lupin’s commitment to be best-in-class in delivering quality products to the communities we serve.”

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.

Lupin has 15 manufacturing sites, 7 research centers.

Read also: Lupin bags USFDA nod for Eslicarbazepine Acetate Tablets for partial-onset seizures

Powered by WPeMatico

NEET MDS 2024: Here Are Top 10 NIRF-Ranked Dental Colleges In India

New Delhi- The National Eligibility and Entrance Test for Masters of Dental Surgery, also known as NEET MDS, was held on March 18, 2024. NEET-MDS is an eligibility-cum-ranking test prescribed as a single entrance test for admission to various MDS courses.

No other entrance examination at the state or institution level will be valid for admission to MDS courses. Candidates have to qualify the NEET-MDS for admission to MDS courses under various universities/institutions in the country.

Every year lakhs of interested students eagerly wait for this examination. Along with this, students also look for top-ranked dental colleges in India.

Also Read: NEET MDS 2024 to be held on March 18, confirms NBE

Here is the list of the top 10 dental colleges in India ranked by the National Institutional Ranking Framework (NIRF) with cut-off percentages-

NIRF RANK

NAME OF THE INSTITUTE

STATE

1

Name of the Institute

Chennai, Tamil Nadu

2

Manipal College of Dental Sciences, Manipal

Manipal, Karnataka

3

Dr. D. Y. Patil Vidyapeeth

Pune, Maharashtra

4

Maulana Azad Institute of Dental Sciences

Delhi, Delhi

5

A.B.Shetty Memorial Institute of Dental Sciences

Mangaluru, Karnataka

6

SRM Dental College

Chennai, Tamil Nadu

7

Sri Ramachandra Institute of Higher Education and Research

Chennai, Tamil Nadu

8

Manipal College of Dental Sciences, Mangalore

Mangalore, Karnataka

9

Siksha `O` Anusandhan

Bhubaneswar, Odisha

10

Jamia Millia Islamia, New Delhi

New Delhi, Delhi

These top 10 ranked medical colleges help students get an exceptional medical education and potentially bright career prospects.

Meanwhile, the minimum qualifying percentage cutoff for NEET MDS 2023 last year, as determined by the NBE, is 50% for the General and EWS categories, 40% for SC, ST, OBC and Reserved PWD categories and 45% for the General PWD/EWS PWD category. The cutoff in all categories had been reduced by 31.807 per cent.

NEET MDS is conducted by the National Board of Examination in Medical Sciences (NBEMS) on March 18, 2024, despite requests for rescheduling and the Supreme Court rejecting the stay petition. Medical Dialogues had earlier reported that MDS aspirants had approached the Supreme Court seeking postponement of the exam and an extension of the deadline to complete the BDS internship. However, the NEET MDS 2024 exam did not get rescheduled, issuing a notice in this regard, the National Board of Examinations (NBE) confirmed that the exam would be conducted on its scheduled date i.e. on 18th March 2024. Meanwhile, based on the directions issued by the Union Health Ministry, NBEMS extended the deadline for completion of the BDS internship till 30th June 2024.

The result is scheduled to be released on 18th April 2024.

Also Read: NEET MDS 2024 not Postponed: Aspirants Approach Supreme Court again

Powered by WPeMatico

Study finds e-cigarette users now more likely to quit traditional cigarettes

A new paper in Nicotine & Tobacco Research finds that smokers who switch to electronic cigarettes are now more likely to stop smoking regular cigarettes. In the past, smokers who began using electronic cigarettes mostly continued smoking. The paper is titled, “Divergence in cigarette discontinuation rates by use of electronic nicotine delivery systems (ENDS): Longitudinal findings from the U.S. PATH Study Waves 1-6.”

Powered by WPeMatico

A paramedic was skeptical about this treatment for stopping repeat opioid overdoses. Then he saw it help

Fire Capt. Jesse Blaire steered his SUV through the mobile home park until he spotted the little beige house with white trim and radioed to let dispatchers know he’d arrived.

Powered by WPeMatico

Doctors on front line of tackling childhood obesity need more training and resources, say researchers

Doctors are feeling unable to tackle the growing problem of childhood obesity due to a lack of training and capacity according to new research.

Powered by WPeMatico

New report presents a global plan to combat prostate cancer

Annual prostate cancer cases worldwide are projected to double by the year 2040, and annual deaths are projected to increase by 85% to almost 700,000 over the same timeframe—mainly among men in low- and middle-income countries. A commissioned report published in The Lancet highlights the future landscape of prostate cancer and seeks to guide cancer experts worldwide on how to manage the massive influx of prostate cancer patients projected over the next two decades.

Powered by WPeMatico

Gut bacteria that strongly influence obesity are different in men and women, study finds

New research being presented at the European Congress on Obesity (ECO) in Venice, Italy (12–15 May) identifies changes in the composition of gut bacteria that may play a key role in the onset and development of obesity, with differences in men and women, which might affect the metabolism of different nutrients and therefore the presence of bioactive molecules in the gut that influence the development of metabolic disease.

Powered by WPeMatico